The estimated Net Worth of Stephen D Chubb is at least $10.3 million dollars as of 23 February 2021. Mr. Chubb owns over 3,530 units of Charles River Laboratories International stock worth over $7,973,391 and over the last 21 years he sold CRL stock worth over $1,994,020. In addition, he makes $308,606 as Independent Director at Charles River Laboratories International.
Stephen has made over 27 trades of the Charles River Laboratories International stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,530 units of CRL stock worth $184,584 on 23 February 2021.
The largest trade he's ever made was exercising 10,710 units of Charles River Laboratories International stock on 2 December 2016 worth over $326,012. On average, Stephen trades about 1,620 units every 59 days since 2003. As of 23 February 2021 he still owns at least 41,187 units of Charles River Laboratories International stock.
You can see the complete history of Mr. Chubb stock trades at the bottom of the page.
Stephen D. Chubb is an Independent Director of Charles River Laboratories International Inc. He is a Special Limited Partner of Catalyst Healthcare Ventures, a venture investment firm specializing in medical devices and diagnostic products, since June 2010. From September 2010 through March 2011, Mr. Chubb served as President and Chief Executive Officer of Allegro Diagnostics, Inc., a privately held molecular diagnostics company focused on the development and future sale of innovative genomic tests for the diagnosis, staging, and guided treatment of lung cancer and lung diseases. Mr. Chubb was previously Chairman and Chief Executive Officer of Matritech, Inc., a publicly traded leading developer of proteomics-based diagnostic products for the early detection of cancer, from its inception in 1987 until December 2007. Mr. Chubb served as President and Chief Executive Officer of T Cell Sciences, Inc. and as President and Chief Executive Officer of Cytogen Corp., both publicly traded biotechnology companies. Mr. Chubb also previously served as Chairman of the Board of Trustees of Mount Auburn Hospital in Cambridge, Massachusetts and as a director of Caregroup Healthcare System, and currently serves as a director of Amylyx Pharmaceuticals Inc. Mr. Chubb has been a director since 1994. Mr. Chubb brings to the Board a wealth of industry and business expertise, drawing upon his 30-year history as a Chief Executive Officer, president and board member at a variety of public and private life sciences companies. The Board benefits particularly from Mr. Chubb's strong biotechnology industry expertise, and he also brings a valued perspective given his service to hospitals and healthcare providers. In addition, as a result of his background as a Certified Public Accountant and prior service as a public company Chief Financial Officer, Mr. Chubb qualifies as an "audit committee financial expert" under SEC guidelines.
As the Independent Director of Charles River Laboratories International, the total compensation of Stephen Chubb at Charles River Laboratories International is $308,606. There are 17 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of $17,722,100.
Stephen Chubb is 76, he's been the Independent Director of Charles River Laboratories International since 1994. There are no older and 20 younger executives at Charles River Laboratories International.
Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman et David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
Charles River Laboratories International executives and other stock owners filed with the SEC include: